EXCELSIOR (4104) Monthly Revenue

Market: TWSE-listed · Industry: Biotech & Medical · 佳醫

EXCELSIOR (4104) reported revenue of NT$1.02 billion for Oct 2026, +38.6% year on year and +6.4% from the previous month. Revenue for Jan–Oct 2026 was NT$8.5 billion (+17.2% year on year).

Revenue for Oct 2026 was a record high (previous high: Sep 2026, NT$960.2 million). →

Year-on-year revenue growth: 5 months in a row. →

In Oct 2026, it ranked No. 5 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$762.8 million24/10Nov 2024 NT$745.4 millionDec 2024 NT$769.7 millionJan 2025 NT$695.6 millionFeb 2025 NT$720.7 million25/02Mar 2025 NT$731.5 millionApr 2025 NT$689.5 millionMay 2025 NT$707 millionJun 2025 NT$769.9 million25/06Jul 2025 NT$713.1 millionAug 2025 NT$714.1 millionSep 2025 NT$771.1 millionOct 2025 NT$737.1 million25/10Nov 2025 NT$764.9 millionDec 2025 NT$774.3 millionJan 2026 NT$805.3 millionFeb 2026 NT$696 million26/02Mar 2026 NT$841.6 millionApr 2026 NT$790.6 millionMay 2026 NT$701.7 millionJun 2026 NT$893.6 million26/06Jul 2026 NT$843.5 millionAug 2026 NT$944.3 millionSep 2026 NT$960.2 millionOct 2026 NT$1.02 billion26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$1.02 billion+38.6%+6.4%
Sep 2026NT$960.2 million+24.5%+1.7%
Aug 2026NT$944.3 million+32.2%+12.0%
Jul 2026NT$843.5 million+18.3%-5.6%
Jun 2026NT$893.6 million+16.1%+27.4%
May 2026NT$701.7 million-0.8%-11.3%
Apr 2026NT$790.6 million+14.7%-6.1%
Mar 2026NT$841.6 million+15.1%+20.9%
Feb 2026NT$696 million-3.4%-13.6%
Jan 2026NT$805.3 million+15.8%+4.0%
Dec 2025NT$774.3 million+0.6%+1.2%
Nov 2025NT$764.9 million+2.6%+3.8%
Oct 2025NT$737.1 million-3.4%-4.4%
Sep 2025NT$771.1 million+4.0%+8.0%
Aug 2025NT$714.1 million+6.7%+0.1%
Jul 2025NT$713.1 million+9.9%-7.4%
Jun 2025NT$769.9 million+6.1%+8.9%
May 2025NT$707 million-4.1%+2.5%
Apr 2025NT$689.5 million-1.0%-5.7%
Mar 2025NT$731.5 million+4.6%+1.5%
Feb 2025NT$720.7 million+25.3%+3.6%
Jan 2025NT$695.6 million-9.4%-9.6%
Dec 2024NT$769.7 million+5.9%+3.3%
Nov 2024NT$745.4 million-4.1%-2.3%
Oct 2024NT$762.8 million+12.2%+2.9%

Jan–Oct 2026 cumulative: NT$8.5 billion (+17.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: EXCELSIOR vs PEC / EXCELSIOR vs Lotus Pharm / EXCELSIOR vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%
GKB1707NT$748.3 million-30.8%

Company remark (original Chinese)

一一五年六月因佳醫創照健康股份有限公司及其子公司成為合併個體,使本月營收增加85,446仟元及本年累計營收增加389,450仟元。

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16